Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) - Stock analysts at William Blair lowered their FY2026 earnings per share estimates for shares of Tarsus Pharmaceuticals in a research note issued to investors on Monday, July 14th. William Blair analyst L. Hanbury-Brown now forecasts that the company will post earnings of $1.67 per share for the year, down from their prior forecast of $1.94. The consensus estimate for Tarsus Pharmaceuticals' current full-year earnings is ($3.17) per share.
Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported ($0.64) EPS for the quarter, topping analysts' consensus estimates of ($0.69) by $0.05. The firm had revenue of $78.34 million for the quarter, compared to analysts' expectations of $72.50 million. Tarsus Pharmaceuticals had a negative return on equity of 39.72% and a negative net margin of 44.91%.
Other equities analysts also recently issued reports about the company. Wall Street Zen downgraded Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 22nd. The Goldman Sachs Group lifted their price target on Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the stock a "neutral" rating in a research report on Monday, May 5th. Oppenheimer began coverage on Tarsus Pharmaceuticals in a research report on Monday, June 2nd. They set an "outperform" rating and a $75.00 target price for the company. HC Wainwright upgraded Tarsus Pharmaceuticals to a "buy" rating and set a $72.00 target price for the company in a research report on Tuesday, May 27th. Finally, Guggenheim boosted their target price on Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the company a "buy" rating in a research report on Friday, May 2nd. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $66.67.
Check Out Our Latest Analysis on Tarsus Pharmaceuticals
Tarsus Pharmaceuticals Stock Performance
Tarsus Pharmaceuticals stock traded up $1.47 during trading on Tuesday, reaching $42.87. The company had a trading volume of 840,829 shares, compared to its average volume of 684,937. Tarsus Pharmaceuticals has a 52 week low of $20.08 and a 52 week high of $57.28. The firm's 50-day simple moving average is $41.89 and its 200 day simple moving average is $46.70. The firm has a market capitalization of $1.80 billion, a price-to-earnings ratio of -15.74 and a beta of 0.80. The company has a current ratio of 5.57, a quick ratio of 5.54 and a debt-to-equity ratio of 0.21.
Hedge Funds Weigh In On Tarsus Pharmaceuticals
Large investors have recently bought and sold shares of the business. Bank of New York Mellon Corp increased its position in shares of Tarsus Pharmaceuticals by 0.5% during the fourth quarter. Bank of New York Mellon Corp now owns 101,928 shares of the company's stock worth $5,644,000 after purchasing an additional 498 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Tarsus Pharmaceuticals by 1.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 293,700 shares of the company's stock worth $16,262,000 after purchasing an additional 3,691 shares in the last quarter. Victory Capital Management Inc. acquired a new position in shares of Tarsus Pharmaceuticals during the fourth quarter worth $223,000. Raymond James Financial Inc. purchased a new stake in shares of Tarsus Pharmaceuticals during the fourth quarter valued at $1,107,000. Finally, HighTower Advisors LLC purchased a new stake in shares of Tarsus Pharmaceuticals during the fourth quarter valued at $207,000. Institutional investors own 90.01% of the company's stock.
About Tarsus Pharmaceuticals
(
Get Free Report)
Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
Further Reading
Before you consider Tarsus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tarsus Pharmaceuticals wasn't on the list.
While Tarsus Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
